Aurinia Pharmaceuticals

Aurinia Pharmaceuticals will present Phase 1 study results for its investigational therapy AUR200 on June 30, 2025. The company, focused on autoimmune diseases, previously launched LUPKYNIS and is developing AUR200 as a dual inhibitor targeting BAFF and APRIL. The findings will be shared via webcast and conference call.